Armistice Capital reports 4.99% stake in Glucotrack

GLUCOTRACK, INC. ownership disclosure: Armistice Capital, LLC and Steven Boyd report 102,115 shares, representing 4.99% of common stock, with shared voting and dispositive power over those shares.

Rhea-AI Filing Summary

GLUCOTRACK, INC. ownership disclosure: Armistice Capital, LLC and Steven Boyd report 102,115 shares, representing 4.99% of common stock, with shared voting and dispositive power over those shares. The filing states the Master Fund has the right to receive dividends or sale proceeds for the reported securities.

Insights

Institutional Ownership Analyst

Armistice Capital reports a sub-5% position with shared control.

Armistice Capital, LLC and Steven Boyd state beneficial ownership of 102,115 shares (4.99%) with shared voting and dispositive power. The filing is an amendment to a Schedule 13G and records the ownership position as of the reported filing.

Distributions rights are attributed to the Master Fund, a client of Armistice Capital; cash‑flow treatment is described as the fund having the right to receive dividends or sale proceeds. Subsequent filings would show any material changes in position.

Corporate Governance Specialist

The filing clarifies joint reporting and attribution of rights to an investment client.

The joint filing statement under Rule 13d-1(k) designates Armistice Capital and Steven Boyd as reporting persons and allocates responsibility for future amendments. The statement preserves each party's responsibility for accuracy regarding its own information.

This is a routine disclosure of a sub-5% passive stake; monitoring future amendments will show increases above regulatory thresholds if they occur.

Key Figures

Shares beneficially owned: 102,115 shares Percent of class: 4.99% Filing date / signature date: May 15, 2026 +1 more

4 metrics

Shares beneficially owned 102,115 shares reported on Schedule 13G/A

Percent of class 4.99% percent of common stock

Filing date / signature date May 15, 2026 date the amendment was signed

CUSIP 45824Q804 Glucotrack common stock CUSIP

Key Terms

Schedule 13G/A, Beneficially owned, Shared dispositive power

3 terms

Schedule 13G/A regulatory

"Amendment No. 1; SCHEDULE 13G/A"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficially owned financial

"Amount beneficially owned: 102,115"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Shared dispositive power regulatory

"Shared Dispositive Power 102,115.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Armistice Capital report in GLUCOTRACK (GCTK)?

Armistice Capital and Steven Boyd report 102,115 shares, equal to 4.99% of common stock, with shared voting and dispositive power as stated in the amendment.

Who holds voting and disposition power for the reported shares?

The filing shows shared voting power of 102,115 shares and shared dispositive power of 102,115 shares for Armistice Capital and Steven Boyd.

Does the filing indicate who receives dividends or sale proceeds for the shares?

Yes. The filing states the Master Fund, an Armistice advisory client, has the right to receive dividends or proceeds from the sale of the reported securities.

When was this Schedule 13G/A signed and filed?

The joint amendment is signed and dated May 15, 2026 by Steven Boyd as Managing Member of Armistice Capital, LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 11:17 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

GLUCOTRACK, INC.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

45824Q804

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 45824Q804

1

Names of Reporting Persons

Armistice Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 102,115.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 102,115.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

102,115.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP Number(s): 45824Q804

1

Names of Reporting Persons

Steven Boyd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 102,115.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 102,115.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

102,115.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: GLUCOTRACK, INC.
(b)	Address of issuer's principal executive offices: 301 Rte. 17 North, Ste. 800, Rutherford, NJ 07070
Item 2.
(a)	Name of person filing: Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
(b)	Address or principal business office or, if none, residence: Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
(c)	Citizenship: Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 45824Q804
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 102,115
(b)	Percent of class: 4.99%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 102,115
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 102,115
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Armistice Capital, LLC

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd - Managing Member
Date:	05/15/2026

Steven Boyd

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd
Date:	05/15/2026

Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: May 15, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd